Roche stands by forecast despite vote against Avastin

Saturday 24 July 2010

The Roche chief executive, Severin Schwan, has confirmed the company expects to see mid-single-digit sales growth in 2010, even taking into account the possible loss of an indication for its lead cancer product, Avastin (bevacizumab).

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Switzerland